BioSenic S.A. (FRA:BT1)

Market Cap	1.50M
Revenue (ttm)	-2.39M
Net Income (ttm)	-4.00M
Shares Out	n/a
EPS (ttm)	-0.01
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	35,005
Average Volume	10,917
Open	0.0022
Previous Close	0.0026
Day's Range	0.0022 - 0.0022
52-Week Range	0.0010 - 0.0173
Beta	n/a
RSI	49.61
Earnings Date	Apr 27, 2026

About BioSenic

BioSenic S.A., a biotechnology company, develops cell therapy products and treatments for autoimmune and inflammatory diseases in Belgium and France. The company’s technologies include arsenic trioxide (ATO) and oral arsenic trioxide (OATO) platforms. It also provides medicinal products, including ArsciMed, an intravenous drug to treat autoimmune diseases. In addition, the company develops ArsciCor, an oral medication in Phase III clinical trial and for the treatment for chronic graft-versus-host disease; JTA-004, an intra-articular injectable ...

• Industry: Biological Products, Except Diagnostic Substances
• CEO: Jean-Luc Vandebroek
• Employees: 7
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: BT1

Financial Performance

In 2024, BioSenic's revenue was 102,000, a decrease of -69.64% compared to the previous year's 336,000. Losses were -4.77 million, -83.43% less than in 2023.